Development of an improved ligand exchange chiral stationary phase based on leucinol for the resolution of proton pump inhibitors.
J Pharm Biomed Anal
; 100: 88-93, 2014 Nov.
Article
em En
| MEDLINE
| ID: mdl-25137653
ABSTRACT
As an effort to develop improved ligand exchange chiral stationary phases (CSPs) for the resolution of chiral drugs, the residual silanol groups on the silica surface of a CSP based on sodium N-[(S)-1-hydroxymethyl-3-methylbutyl]-N-undecylaminoacetate, a (S)-leucinol derivative, were protected with n-octyl groups. The residual silanol group-protected CSP was applied to the resolution of proton pump inhibitors (PPIs) such as omeprazole, pantoprazole, lansoprazole and rabeprazole. The resolution of PPIs on the residual silanol group-protected CSP was excellent with the separation factors (α) in the range of 4.32-6.42 and the resolution factors (RS) in the range of 6.70-7.15. The improved chiral recognition ability of the residual silanol group-protected CSP was rationalized to be originated from the protection of the non-enantioselective interaction sites on the silica surface and the improved lipophilicity of the stationary phase.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Cromatografia Líquida de Alta Pressão
/
Inibidores da Bomba de Prótons
/
Leucina
Idioma:
En
Revista:
J Pharm Biomed Anal
Ano de publicação:
2014
Tipo de documento:
Article